Adingupu et al. [16] demonstrated that SGLT2 inhibitor treatment improved coronary flow velocity reserve based on isoflurane-induced hyperemia and ultrasound imaging in an ob/ob-/- mouse model of obesity. Here, SLC5A2 is linked to obesity due to melanocortin 4 receptor deficiency.